

研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
金倉 譲 松村 到	血液疾患	白砂兼光、 古郷幹彦	口腔外科学 第4版 (3刷)	医歯薬出版 株式会社	東京	2022	431-463
石田文宏	赤芽球癆		呼吸器症候群 (第3版), -その 他の呼吸器疾患 を含めて- 各種 疾患に見られる 呼吸器病変	日本臨牀 社	東京都	2021	337-343
川端浩	骨髄異形成症候群	矢崎義雄、 小室一成、 渥美達也、 神田 隆、 神田善伸、 木下芳一、 須永真司、 竹内靖博、 竹原徹郎、 南学正臣、 長谷川好規 松本哲哉、 楽木宏実、 綿田裕孝	内科学 第12版	朝倉書店	東京	2022	V-77-80
鈴木隆浩	骨髄異形成症候群	日本臨床腫 瘍学会	新臨床腫瘍学 (改訂第6版)	南江堂	東京	2020	598-602
井上義一	ランゲルハンス細 胞組織球症	矢崎義雄、 徳田安春、 浅野浩一 郎、筒井裕 之、松本主 之、持田智、 荒木栄一、 柴田洋孝、 神田善伸、 深川雅史、 富本秀和、 藤田次郎、 永田真、上 阪等、上條 吉人	新臨床内科学 [デスク版]	株式会社 医学書院	東京	2020	197-199

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yoroidaka T, Hosokawa K, Imi T, Mizumaki H, Katagiri T, Ishiyama K, Yamazaki H, Azuma F, Nanya Y, Ogawa S, Nakao S.	Hematopoietic stem progenitor cells lacking HLA differ from those lacking GPI-anchored proteins in the hierarchical stage and sensitivity to immune attack in patients with acquired aplastic anemia.	Leukemia	35	3257-3267	2021
Tanabe M, Hosokawa K, Nguyen MAT, Nakagawa N, Maruyama K, Tsuji N, Uru shihara R, Espinoza L, Elbadry MI, Mohiuddin M, Katagiri T, Ono M, Fujiwara H, Chonabayashi K, Yoshida Y, Yamazaki H, Hirao A, Nakao S.	The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-beta.	Leukemia	36	847-855	2022
Tsuji N, Hosokawa K, Uru shihara R, Tanabe M, Katagiri T, Ozawa T, Takamatsu H, Ishiyama K, Yamazaki H, Kishi H, Ogawa S, Nakao S.	Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15.	Leukemia		doi: 10.1038/s41375-022-01549-6	2022
Hori A, Ishida F, Nakazawa H, Yamaura M, Morita S, Uehara T, Honda T, Hidaka H.	Serum sphingomyelin species profile is altered in hematological malignancies.	Clinical Chemistry Acta	514	29-33	2021
Nakazawa H, Yamaguchi T, Sakai H, Maruyama M, Kawakami T, Kawakami F, Nishina S, Ishikawa M, Koshio T, Ishida F.	A novel germline GAG2 frameshift mutation with a premature stop codon in a family with congenital sensory hearing loss and myelodysplastic syndrome.	Int J Hematol	114	286-291	2021
Bhattacharya D, Teramo A, Gasparini VR, Huuhtanen J, Kim D, Theodoropoulos J, Schiavoni G, Barilà G, Vicenzetto C, Calabretto G, Fallico M, Kawakami T, Nakazawa H, Falini B, Tiacchi E, Ishida F, Semenzato G, Kelkka T, Zambello R, Mustjoki S	Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia.	Int J Blood Cancer J	12	31	2022
Nishimura JI, Ando K, Masuko M, Noji H, Ito Y, Mayer J, Griskevicius L, Bucher C, Müllershausen F, Gergely P, Rozenberg I, Schubart A, Chawla R, Rondeau JM, Roguska M, Splawski I, Keating MT, Johnson L, Danekula R, Bagger M, Watanabe Y, Haraldsson B, Kanakura Y.	Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.	Haematologica		doi: 10.3324/haematol.2020.265868.	2022

Ikezoe T, Noji H, Ueda Y, Kanda Y, Okamoto S, Usuki K, Matsuda T, Akiyama H, Shimono A, Yonemura Y, Kawaguchi T, Chiba S, Kanakura Y, Nishimura JI, Ninomiya H, Obara N.	Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan.	Int J Hematol	115	470-480	2022
Hosokawa K, Ishiyama K, Ikemoto T, Sugimori C, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Nguyen MAT, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura JI, Kanakura Y, Nakao S.	The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure.	Ann Hematol	100	1975-1982	2021
Shibata S, Inano S, Watanabe M, Fujiwara K, Ueno H, Nannya Y, Kanda J, Kawasaki N, Okamoto Y, Takiuchi Y, Fukunaga A, Tabata S, Ogawa S, Takaori-Kondo A, Kitano T.	Identification of an asymptomatic Shwachman-Bodian-Diamond syndrome mutation in a patient with acute myeloid leukemia.	Int J Hematol	115	428-434	2022
Matsuo H, Wakita T, Hiramatsu H, Ohmori K, Kodama K, Nakatani K, Kamikubo Y, Iwamoto S, Kondo T, Takaori-Kondo A, Takita J, Tomizawa D, Taga T, Adachi S.	Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.	Br J Haematol	192	e7-e11	2021
Okamoto Y, Abe M, Mu A, Tempaku Y, Rogers CB, Mochizuki AL, Katsuki Y, Kanemaki MT, Takaori-Kondo A, Sobeck A, Bielinsky AK, Takata M.	SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells.	Blood	137	336-348	2021
Shimizu T, Kondo T, Nannya Y, Watanabe M, Kitawaki T, Shindo T, Hishizawa M, Yamashita K, Ogawa S, Takaori-Kondo A.	Next-generation sequencing in two cases of de novo acute basophilic leukaemia.	J Cell Mol Med	25	7095-7099	2021
Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuo KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kanda J, Fukuda T, Arita Y, Aoki J.	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.	Bone Marrow Transplant	56	3008-3015	2021
Asou C, Maeda T, Ishikawa M, Okamura D, Kohri M, Takahashi M, Tsukasaki K, Sakaguchi H, Satoh T, Kayano H, Akira Matsuda A, Asou N.	Paravertebral extramedullary hematopoiesis in a case of myelodysplastic syndrome with ring sideroblasts and an SF3B1 mutation.	Int J Hematol		doi: 10.1007/s12185-022-03291-2.	2022

Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S, Kuribayashi W, Oshima M, Nakajima-Takagi Y, Yamashita M, Mimura N, Becker H, Izawa K, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Lennox W, Sheedy J, Weetall M, Sakaida E, Yokote K, Iwama A.	DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.	Blood Adv	5	438-450	2021
Fujishima N, Kohmaru J, Koyota S, Kuba K, Saga T, Omokawa A, Moritoki Y, Ueki S, Ishida F, Nakao S, Matsuda A, Ohta A, Tohyama K, Yamasaki H, Usuki K, Nakashima Y, Sato S, Miyazaki Y, Nannya Y, Ogawa S, Sawada K, Mitani K, Hirokawa M.	Clonal hematopoiesis in adult pure red cell aplasia.	Sci Rep	11	e2253	2021
Shafiee S, Gelebart P, Popa M, Hellesøy M, Hovland R, Brendsdal Forthun R, Lee J, Tohyama K, Molven A, Parekkadan B, Tore Gjertsen B, Olsnes Kittang A, McCormack E.	Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line.	Br J Haematol	193	415-419	2021
Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y, Fukuda-Kurahashi Y, Yoshida-Sakai N, Hattori N, Hayashi Y, Kawaguchi A, Tohyama K, Okada S, Harada H, Ushijima T, Kimura S.	Silylation of deoxynucleotide analog yields an orally available drug with antileukemia effects.	Mol Cancer Ther	20	1412-1421	2021
Kurozumi N, Tsujioka T, Ouchida M, Sakakibara K, Nakahara T, Suemori SI, Takeuchi M, Kitanaka A, Shibakura M, Tohyama K.	VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines.	Cancer Sci	112	3302-3313	2021
Yanagisawa H, Kawabata H, Ueda Y, Arita K, Iwao-Kawanami H, Sakai T, Kawanami T, Yamada K, Mizuta S, Fukushima T, Masaki Y.	Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes.	Int J Hematol		doi: 10.1007/s12185-022-03321-z.	2022
Morimoto Y, Chonabayashi K, Kawabata H, Okubo C, Yamasaki-Morita M, Nishikawa M, Narita M, Inagaki A, Nakanishi K, Nagao M, Takaori-Kondo A, Yoshida Y.	Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia.	Blood Adv	6	1100-1114	2022
Nakazaki K, Takezaki T, Masamoto Y, Miyazaki Y, Mitani K, Kurokawa M.	Nationwide Survey of Lower Risk Myelodysplastic Syndromes in Japan.	Blood	138	4662	2021

Hayama K, Abe Y, Kamata H, Okina S, Murakami Y, Kanoh Y, Suzuki T.	Bone marrow ring sideroblasts in hematological disease: an analysis of consecutive 1300 samples in a single institution.	Int J Hematol	115	508-514	2022
Tsutsue S, Suzuki T, Kim H, Crawford B.	Real world assessment of myelodysplastic syndrome: Japanese claims data analysis.	Future Oncol	18	93-104	2022
Yamauchi T, Miyawaki K, Semba Y, Takahashi M, Izumi Y, Nogami J, Nakao F, Sugio T, Sasaki K, Pinello L, Bauer DE, Bamba T, Akashi K, Maeda T.	Targeting leukemia-specific dependence on the de novo purine synthesis pathway in leukemia.	Leukemia	36	383-393	2022
Yoshimoto G, Mori Y, Kato K, Odawara J, Kuriyama T, Ueno T, Obara T, Yurino A, Yoshida S, Ogawa R, Ohno Y, Iwasaki H, Eto T, Akashi K, Miyamoto T.	Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.	Leuk Lymphoma	62	2939-2948	2021
Miyawaki K, Kato K, Sugio T, Sasaki K, Miyoshi H, Semba Y, Kikushige Y, Mori Y, Kunisaki Y, Iwasaki H, Miyamoto T, Kuo FC, Aster JC, Ohshima K, Maeda T, Akashi K.	A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of DLBCL.	Blood Adv		doi: 10.1182/bloodadvances.	2022
Akahane K, Shirai K, Wakatsuki M, Suzuki M, Hatanaka S, Takahashi Y, Kawahara M, Ogawa K, Takahashi S, Oyama-Manabe N, Ashizawa M, Kimura SI, Kakeo S, Kanda Y.	Dosimetric evaluation of ovaries and pelvic bones associated with clinical outcomes in patients receiving total body irradiation with ovarian shielding.	J Radiat Res	62	918-925	2021
Nishimura A, Hirabayashi S, Hasegawa D, Yoshida K, Shiraishi Y, Ashiarai M, Hosoya Y, Fujiwara T, Harigae H, Miyano S, Ogawa S, Manabe A.	Acquisition of monosomy 7 and a RUNX1 mutation in Pearson syndrome.	Pediatr Blood Cancer	68	e28799	2021
Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Mörnicke A, Boer JM, Cavé H, Cazzaniga G, Yeoh AEJ, Sanada M, Imamura T, Inaba H, Mullighan C, Loh ML, Norén-Nyström U, Pastorczak A, Shih LY, Zaliouva M, Pui CH, Haas OA, Harrison CJ, Moorman AV, Manabe A.	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: A retrospective analysis by the Ponte di Legno Childhood ALL Working Group.	Leukemia	35	3272-3277	2021
Hama A, Hasegawa D, Manabe A, Nozawa K, Narita A, Muramatsu H, Kosaka Y, Kobayashi M, Koh K, Takahashi Y, Watanabe K, Ohara A, Ito M, Kojima S.	Prospective validation of the provisional entity of refractory cytopenia of childhood, proposed by the World Health Organization.	Br J Haematol	196	1031-1039	2022

Honda Y, Muramatsu H, N anjo Y, Hirabayashi S, Meg uro T, Yoshida N, Kakuda H, Ozono S, Wakamatsu M, Moritake H, Yasui M, San o H, Manabe A, Sakashita K.	A retrospective analysis of a zacididine treatment for juve nile myelomonocytic leukemi a.	Int J He matol	115	263-268	2022
Niitsuma-Sugaya I, Kanamo ri H, Ichikawa S, Fukuhara N, Seike I, Takei K, Baba H, Oshima K, Aoyagi T, H arigae H, Tokuda K.	Disseminated gonococcal infe ction in a patient with paro xyssmal nocturnal haemoglob inuria receiving eculizumab.	Lancet Inf ect Dis	21	741	2021
Ichikawa S, Fujiwara T, Sa ito K, Fukuhara N, Yokoya ma H, Hatta S, Onodera K, Onishi Y, Fujishima F, Ich inohasama R, Harigae H.	A novel case of $\gamma\delta$ T cell le ukemia with recurrent gene tic abnormalities accompanie d by agranulocytosis.	Ann Hem atol	100	2665-2668	2021
Onishi Y, Onodera K, Fuku hara N, Kato H, Ichikawa S, Fujiwara T, Yokoyama H, Yamada-Fujiwara M, Ha rigae H.	Unrelated cord blood transpl antation for adult-onset EB V-associated T-cell and NK- cell lymphoproliferative diso rders.	Int J He matol		doi: 10.10 07/s12185- 022-03313 -z.	2022
佐藤亜紀、東條有伸	ランゲルハンス細胞組織球症 の基礎と臨床	血液内科	83	50~56	2021
Flaherty KR, Wells AU, Cot tin V, Devaraj A, Inoue Y, Richeldi L, Walsh SLF, Kol b M, Koschel D, Moua T, S towasser S, Goeldner RG, S chlenker-Herceg R, Brown KK; INBUILD trial investig ators.	Nintedanib in progressive in terstitial lung diseases: data from the whole INBUILD t rial.	Eur Respi r J		doi: 10.11 83/139930 03.04538-2 020.	2022
Birring SS, Bushnell DM, B aldwin M, Mueller H, Male N, Rohr KB, Inoue Y.	The psychometric properties of the King's Brief Interstit ial Lung Disease questionna ire and thresholds for mean ingful treatment response in patients with progressive fi brosing interstitial lung dise ases.	Eur Respi r J		doi: 10.11 83/139930 03.01790-2 021.	2021
井上義一	成人の肺ランゲルハンス組織 細胞球症	呼吸器症候 群 (第3版) III	2021 年別 冊 N o.19	154-159	2021